These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 31236818)

  • 21. Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment.
    Kuo YY; Ho KH; Shih CM; Chen PH; Liu AJ; Chen KC
    Life Sci; 2022 Nov; 309():121023. PubMed ID: 36202175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.
    Liu B; Liu J; Liao Y; Jin C; Zhang Z; Zhao J; Liu K; Huang H; Cao H; Cheng Q
    Med Sci Monit; 2019 May; 25():3624-3635. PubMed ID: 31094363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.
    Yamamoto Y; Sasaki N; Kumagai K; Takeuchi S; Toyooka T; Otani N; Wada K; Narita Y; Ichimura K; Namba H; Mori K; Tomiyama A
    Neurol Med Chir (Tokyo); 2018 Jul; 58(7):296-302. PubMed ID: 29899179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
    Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
    Yang B; Ma YB; Chu SH
    Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
    Chen JC; Lee IN; Huang C; Wu YP; Chung CY; Lee MH; Lin MH; Yang JT
    BMC Cancer; 2019 Aug; 19(1):756. PubMed ID: 31370819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
    Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
    J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme.
    Meng J; Qian W; Yang Z; Gong L; Xu D; Huang H; Jiang X; Pu Z; Yin Y; Zou J
    BMC Cancer; 2024 Mar; 24(1):317. PubMed ID: 38454344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
    Gao YT; Chen XB; Liu HL
    Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer.
    Li X; Ji Y; Han G; Li X; Fan Z; Li Y; Zhong Y; Cao J; Zhao J; Zhang M; Wen J; Goscinski MA; Nesland JM; Suo Z
    BMC Cancer; 2016 Nov; 16(1):894. PubMed ID: 27852261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
    Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
    Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
    Nam Y; Koo H; Yang Y; Shin S; Zhu Z; Kim D; Cho HJ; Mu Q; Choi SW; Sa JK; Seo YJ; Kim Y; Lee K; Oh JW; Kwon YJ; Park WY; Kong DS; Seol HJ; Lee JI; Park CK; Lee HW; Yoon Y; Wang J
    Genome Med; 2023 Mar; 15(1):16. PubMed ID: 36915208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
    Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
    Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Evaluation of Glioblastoma Cell Dissociation and Its Influence on Its Behavior.
    Skarkova V; Krupova M; Vitovcova B; Skarka A; Kasparova P; Krupa P; Kralova V; Rudolf E
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishment of a Novel Temozolomide Resistant Subline of Glioblastoma Multiforme Cells and Comparative Transcriptome Analysis With Parental Cells.
    Ha HA; Yang JS; Tsai FJ; Li CW; Cheng YD; Li J; Hour MJ; Chiu YJ
    Anticancer Res; 2021 May; 41(5):2333-2347. PubMed ID: 33952458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies.
    Menyhárt O; Fekete JT; Győrffy B
    Carcinogenesis; 2021 Jun; 42(6):804-813. PubMed ID: 33754151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.